CYP2E1 Lentiviral Activation Particles (m): sc-419917-LAC
- Target species: mouse
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- CYP2E1 Lentiviral Activation Particles (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- CYP2E1 Lentiviral Activation Particles (m) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by CYP2E1 Lentiviral Activation Plasmid (m) and CYP2E1 Lentiviral Activation Plasmid (m2) target distinct regulatory regions of the Cyp2e1 promoter. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CYP2E1 Lentiviral Activation Particles (m) | sc-419917-LAC | 200 µl | $455.00 |
Mouse Cyp2e1 encodes CYP2E1, a microsomal cytochrome P450 enzyme that catalyzes the oxidation of small molecules and endogenous substrates within hepatic and extrahepatic tissues. CYP2E1 activity is closely linked to NADPH-dependent electron transfer and can elevate reactive oxygen species, connecting this enzyme to oxidative stress, lipid peroxidation, and cellular redox homeostasis. Through interactions with xenobiotic metabolism, fatty acid oxidation, and inflammatory signaling, altered CYP2E1 expression is frequently examined in models of steatosis, toxicant-induced liver injury, insulin resistance, and neuroinflammation. As a regulator of metabolic bioactivation and stress responses, Cyp2e1 is widely studied for its impact on mitochondrial function, ER stress, and transcriptional programs that shape tissue susceptibility to injury.
CYP2E1 Lentiviral Activation Particles (m) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient Cyp2e1 upregulation across a broader range of human cell types.
CYP2E1 Lentiviral Activation Particles (m) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the Cyp2e1 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous CYP2E1 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native Cyp2e1 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.